Novo Nordisk Recognised For Improving Access To Medicine

Primary tabs

Novo Nordisk Recognised For Improving Access To Medicine

Ranking makes it evident that improving access to medicine and availability of care is an integral part of Novo Nordisk's way of doing business.
tweet me:
Check out our proud recognition for #access to medicine and care! #sustainability #ATMIndex2012 @ATMIndex

Multimedia from this Release

Wednesday, November 28, 2012 - 9:00am

CONTENT: Press Release

Nov. 28, 2012 /3BL Media/ - Today, Novo Nordisk moves up two places to number 6 in the 2012 Access to Medicine Index.  According to the Access to Medicine Foundation, a Netherlands-based non-profit organisation, Novo Nordisk’s improved score is a reflection of its access-oriented approach to public policy, patents and philanthropy as well as the company’s equitable pricing initiatives for its diabetes medicines.

“Improving access to medicine and availability of care is an integral part of our way of doing business. We are pleased with our new ranking and will continuously strive to do more to meet the unmet global health needs,” says Charlotte Ersbøll, corporate vice president, Global Stakeholder Engagement, Novo Nordisk. 

Leading practices and areas for improvement

The 2012 Index highlighted Novo Nordisk’s leading practices in tiered pricing schemes for insulin greater than any differential disclosed by peers; it having one of the largest pipelines dedicated to diabetes products for both innovative and adaptive research and development; and its monitoring of stakeholder engagement globally.

Novo Nordisk’s Changing Diabetes® programmes and innovation projects, including Changing Diabetes® in Children and the Base of the Pyramid project, were highlighted as leading initiatives building healthcare capacity and improving access to medicine.

The Index also suggested areas where Novo Nordisk should focus efforts for continued improvement, including more transparency about lobbying activities in relevant countries and developing distinct packaging to prevent product diversion.

 “We are grateful to the Access to Medicine Foundation for their feedback and we share their desire to address the health needs of people in low- and middle-income countries. Our contribution is to make a sustainable change to people with diabetes no matter where they live in the world,” says Charlotte Ersbøll.

About the Access to Medicine Index

The Access to Medicine Index is a global initiative aimed at advancing access to medicine in developing countries by stimulating the pharmaceutical industry to do more to meet the unmet needs in low- and middle-income countries.

View the full 2012 Access to Medicine Index

Read more about Novo Nordisk’s approach to access to diabetes care

Keywords: Pharma News, Research & Solutions | Access to Medicine Index | Medicine | Novo Nordisk | Pharma News, Research & Solutions | csr | sustainability

CONTENT: Press Release